Related Experiment Video
Updated: Jun 27, 2026
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
Emerging antiangiogenic treatments for gliomas - efficacy and safety issues
Jörg Dietrich1, Andrew D Norden, Patrick Y Wen
1Division of Neuro-Oncology, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
Purpose Of Review:
To review the rationale and recent experience of angiogenesis inhibitors in malignant gliomas and to highlight both the promise and potential complications of these agents.
Recent Findings:
Several new agents targeting angiogenesis in malignant gliomas have become available and have been increasingly used to complement conventional chemotherapy. Specifically, bevacizumab, often in combination with irinotecan, has demonstrated favorable results in achieving significant radiographic responses and in prolonging progression-free survival in patients with recurrent malignant glioma.
Summary:
Antiangiogenic drugs have been shown to have promising activity in recurrent malignant gliomas. Investigation of novel antiangiogenic compounds and future clinical trials will determine whether these drugs have a role in first-line therapy. This article reviews the rationale for targeting angiogenesis in malignant brain tumors and summarizes the results of recent clinical trials. In addition, this review will outline potential toxicities associated with angiogenesis inhibition in an attempt to provide practical guidance to physicians treating patients with malignant gliomas.
Insights
Angiogenesis inhibitors show promise for treating malignant gliomas, particularly bevacizumab. Further research will clarify their role in first-line therapy and potential toxicities.
Area of Science:
- Neuro-oncology
- Cancer biology
- Pharmacology
Background:
- Malignant gliomas are aggressive brain tumors with limited treatment options.
- Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and progression.
- Targeting angiogenesis offers a novel therapeutic strategy for brain tumors.
Purpose of the Study:
- To review the rationale for using angiogenesis inhibitors in malignant gliomas.
- To summarize recent clinical experiences with these agents.
- To highlight their potential benefits and complications.
Main Methods:
- Review of current literature on angiogenesis inhibitors in malignant gliomas.
- Analysis of clinical trial data for agents like bevacizumab.
- Discussion of toxicities and practical guidance for clinicians.
Main Results:
- Bevacizumab, often with irinotecan, shows significant radiographic responses and prolonged progression-free survival in recurrent malignant glioma.
- New anti-angiogenic agents are increasingly used alongside conventional chemotherapy.
- These drugs demonstrate promising activity in recurrent malignant gliomas.
Conclusions:
- Anti-angiogenic drugs show promise in recurrent malignant gliomas.
- Future trials will assess their role in first-line therapy.
- Understanding and managing potential toxicities is crucial for effective treatment.
